Oral typhoid vaccines are live, attenuated bacterial vaccines given orally to prevent infection by Salmonella typhi, the bacteria that causes typhoid fever. Rising demand for oral typhoid vaccines to protect populations living in or traveling to endemic areas is driving the growth of the market. Oral typhoid vaccines have advantages over injectable typhoid vaccines as they can be self-administered, create both mucosal and systemic immunity and have a relatively good safety profile.
The global Oral Typhoid Vaccine Market is estimated to be valued at US$ 394.62 Bn in 2023 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends propelling the growth of the oral typhoid vaccine market is increasing government initiatives for typhoid control in endemic regions. Typhoid fever is a major public health concern in developing countries of Asia, Africa and Latin America where access to clean water and proper sanitation is limited. National and global health organizations are collaborating with governments on mass vaccination campaigns and immunization programs to control typhoid outbreaks. For example, Bharat Biotech’s live attenuated typhoid conjugate vaccine Typbar-TCV has been prequalified by WHO in 2018 and recommended for routine use in typhoid-endemic countries. Several developing countries in Asia and Africa have introduced Typbar-TCV in their routine childhood immunization programs with financial support from GAVI and global health partners. Such initiatives aim to protect vulnerable populations at highest risk and help eliminate typhoid in endemic regions through widespread use of effective vaccines.
Strength: Oral typhoid vaccine offers an alternative to injections providing greater accessibility and convenience especially in remote areas. It also eliminates usage and safe disposal of needles and syringes making vaccination programs easier to implement.
Weakness: Lower efficacy compared to injections require multiple doses for adequate protection over the recommended time period. Vaccine hesitancy and lack of awareness in some regions can affect uptake.
Opportunity: High disease burden in low and middle income countries represents significant market potential. Expansion of vaccination programs fueled by initiatives like Gavi support increased demand. Transition from injections to oral vaccine adoption worldwide bodes well for future growth.
Threats: Threat from other enteric infections that are difficult to differentiate clinically from typhoid poses diagnostic challenges. Continued anti-microbial resistance seen in Salmonella Typhi bacteria necessitates regular vaccine updates to address emerging strains.
The global oral typhoid vaccine market is expected to witness high growth over the forecast period driven by initiatives to strengthen routine immunization programs especially in developing nations bearing substantial typhoid disease burden.
Regional analysis: Asia Pacific currently dominates due to large populations and prevalence of typhoid in India, Pakistan, Indonesia and the Philippines. Increasing vaccination rates supported by government programs and the WHO’s Esther Alliance is boosting the regional market.
Key players: Key players operating in the oral typhoid vaccine market are Sanofi Pasteur, Bharat Biotech, Pfizer Inc., GlaxoSmithKline (GSK), Baxter International Inc., Merck & Co., Inc. (MSD outside North America), Takeda Pharmaceutical Company Limited, Novartis International AG, Biological E. Limited, AstraZeneca, Cipla Limited, Prokarium, Bio-Med Pvt. Ltd., Panacea Biotec, Dynavax Technologies Corporation, Butantan Institute, Zydus Cadila, Biomed Pvt. Ltd., Cadila Healthcare Limited, GlaxoSmithKline Biologicals. These companies are focusing on expanding their oral typhoid vaccine portfolio through collaborations and new product launches.
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it